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	We report on the first well-tolerated and successful use of sofosbuvir-based therapy in a patient in whom chronic infection with hepatitis C had preceded the development of B-cell non-Hodgkin’s lymphoma. The patient had previously failed numerous attempts to clear the hepatitis C virus with traditional antiviral schedules. 
	We demonstrate that sofosbuvir-based therapy resulted in cure of hepatitis C in a patient who had relapsed during combination therapy with an NS5A inhibitor, an NS3 protease inhibitor and ribavirin, as well as treatment failures to multiple courses of interferon-based therapy. This report also suggests that eradication of hepatitis C virus may result in the short-term prevention of B-cell non-Hodgkin’s lymphoma relapse. The findings from our case require further validation in future cohorts of patients.











WHY THIS CASE IS IMPORTANT
The effects of hepatitis C virus (HCV) on liver-related morbidity and mortality are well documented; however, the virus also results in extrahepatic manifestations including B-cell non-Hodgkin’s lymphoma (B-NHL) [1–3]. In this study we describe a patient with HCV and B-NHL. Treatment of B-NHL patients infected with HCV, using antiviral therapy such as pegylated interferon (PEG-IFN) and ribavirin (RBV), has demonstrated that clearance of HCV is associated with lymphoma regression [3,4]. Furthermore, virological relapse in these patients results in recurrence of lymphoma, supporting a cause-and-effect relationship between HCV infection and B-NHL [3]. 
The advent of direct-acting antiviral agents (DAAs) has revolutionised anti-HCV therapy and resulted in increasing rates of sustained virological response (SVR). However, current guidelines do not provide recommendations about HCV eradication in patients with extrahepatic complications, such as B-NHL, in whom antiviral agents are not licensed; therefore, the potential to use DAAs in these patients remains unexplored [5,6].
In this study we describe for the first time use of a DAA, sofosbuvir (SOF), in a patient with HCV and B-NHL who had previously failed several courses of antiviral therapy. 

CASE DESCRIPTION















Table 1. Treatment history of the patient’s HCV infection and B-NHL 1994–2013. Details of treatment regimens and clinical status of HCV infection and B-NHL from the time of diagnosis of HCV infection (1994) until referral to our clinic.
Date	Treatment regimen	HCV clinical status	B-NHL 
clinical status	Clinical notes
1994–2002	IFN-α; IFN-α-n1 + RBV + amantadine; IFN-α-2a + RBV + amantadine	Viral relapse	-	-
2003	-	-	-	No evidence of fibrosis, minimal inflammation on biopsy (Ishak grade 3, stage 0)
May 2006	-	HCV RNA 8.7 x 106 IU/mL	Diagnosed 
B-NHL 
(Grade 2–3)	-
July 2006–January 2007	6 courses of R-CHOP chemotherapy 
(cyclophosphamide + doxorubicin + vincristine + prednisone) + rituximab	- 	Complete remission of lymphoma	-
May 2007–May 2008	PEG-IFN-α-2b 100µg/week + RBV 800mg/day	Non-responsive HCV RNA 1.3 x 106 IU/mL 
(at EOT)	Lymphoma relapsed February 2008	Began radiotherapy February 2008 
June 2011	PEG-IFN-α-2a 180µg/week + RBV 1000mg/day; Radiotherapy	HCV RNA 3.4 x 106 IU/mL (start of therapy); HCV RNA462 IU/mL 
(at EOT) outcome non-responder	-	Pancytopenia,DDIs
March 2012–
July 2012	4 courses of rituximab and bendamustine	-	Remissionof lymphoma	-
January 2013–July 2013	PEG-IFN-α-2b 80µg/week + RBV 800mg/day	HCV RNA 3.6 x 106 IU/mL (start of therapy); viral clearance not achieved at EOT	-	Enlarged lymph nodes: biopsy confirmed presence of lymphoma (Grade 2–3)
August 2013	Rituximab 500mg/day and ibritumomab tiuxetan	-	-	Remissionof lymphoma
B-NHL: B-cell non-Hodgkin’s Lymphoma; DDI: drug–drug interaction; EOT: end of therapy; HCV: hepatitis C virus; IFN: interferon; PEG-IFN: pegylated interferon; RBV: ribavirin


	PEG-IFN-based HCV therapy began again in January 2013 in response to elevated transaminase values and high viral load. Viral load decreased, however, assessment of enlarged lymph nodes indicated the lymphoma had relapsed. Viral load continued to decrease at each subsequent assessment but was not cleared (HCV RNA <12 IU/mL) and antiviral therapy was stopped in July. Combination therapy with rituximab 500mg/day and ibritumomab tiuxetan was started in August resulting in lymphoma remission. The patient was referred to our clinic at Baggiovara Hospital (NOCSAE) in October 2013 for re-assessment of his HCV therapy options. 

	An experimental anti-HCV treatment regimen was proposed combining two DAAs which act on different targets of the HCV replication cycle to increase potency and reduce the potential for viral resistance. The combination of the NS5A replication inhibitor daclatasvir (DCV), the NS3 protease inhibitor (PI) asunaprevir (ASV), and RBV has been shown to be effective in patients with HCV GT 1b infection [7,8]. 











Table 2. Patient viral load and transaminase levels at each clinical assessment throughout the duration of DAA therapy. 
Table details the drug regimen at each clinical time point alongside viral load (HCV RNA [IU/mL]) and transaminase values (AST/ALT U/L). Assessments were taken from 21 January 2014 until 29 December 2014, from the start of DAA-based therapy until 6 months after the end of treatment. 
Treatment regimen	Date	HCV RNA (IU/mL)	Transaminases (AST/ALT) U/L
DCV 60mg/day + ASV 400mg/day + 
RBV 800mg/day	21.01.14	2,577,923 	213/337 
	29.01.14	271 	39/100 
	18.02.14	596,847	186/339 
DCV 60mg/day + ASV 400mg/day + 




DCV 60mg/day + 
RBV 800mg/day + 
PEG-IFN-α-2a 180µg/week	11.03.14	4,024	51/76
SOF 400mg/day + DCV 60mg/day + RBV 1000mg/day + PEG-IFN-α-2a 180µg/week	15.03.14	389 	NA
	18.03.14	Positive <12	41/51
SOF 400mg/day + 









Month 1 after D/C	04.07.14	Negative <12	24/21 
Month 3 after D/C	05.09.14	Negative <12	31/27
Month 6 after D/C	29.12.14	Negative <12	39/32 

ALT: alanine aminotransferase; AST: aspartate aminotransferase; ASV: asunaprevir; D/C: discontinuation; DCV: daclatasvir; NA: not available; PEG-IFN: pegylated interferon; RBV: ribavirin; SOF: sofosbuvir

	Drug resistance analysis demonstrated the patient had developed resistance to ASV (D168V mutation in NS3) and further revealed the patient was infected with HCV GT 4d, not 1b (limitation of genotyping method available before 2011 – INNO-LiPa). ASV was omitted on 11 March and replaced with the pangenotypic NS5B polymerase inhibitor SOF on 15 March for an intended duration of 12 weeks. Clinical assessment 3 days later demonstrated the patient’s viral load had decreased to <12 IU/mL. Genotypic analysis revealed the patient had developed DCV resistance (M31M/V and Y93H/Y mutations in NS5A) and DCV was suspended on 19 March. The patient continued on a regimen of SOF + RBV + PEG-IFN and 8 days after the introduction of SOF showed negative viraemia (qualitative HCV RNA negative; <12 IU/mL) which was maintained at Weeks 1, 2, 4, 6, 7, 9, 12 and 24. Neuropathic pain and paraesthesia associated with PEG-IFN-α-2a persisted although the patient experienced no additional side effects. There was no biochemical evidence for treatment intolerance; transaminase levels remained proportional to the level of viraemia and complete blood count values ​were mostly stable throughout (haemoglobin 11g/dL, ~4 points lower than pre-treatment values; white blood cells approximately 2000/mm3; neutrophils >1100/mm3). Renal and thyroid function and indices of cholestasis showed no significant alterations as assessed through routine laboratory evaluation. Accordingly, the therapeutic regimen was continued for the planned 12 weeks. 
HCV RNA was undetectable on assessing the patient’s viral load 1, 3 and 6 months after completing the SOF-based regimen indicative of an SVR – the patient was considered cured of HCV [6]. Transaminase levels and other laboratory parameters also remained stable during this time and no side effects were reported. There was no evidence of lymphoma relapse 3 months after the discontinuation of HCV therapy and lymphoma remains in remission at the time of press. 

OTHER SIMILAR AND CONTRASTING CASES IN THE LITERATURE
To our knowledge this is the first example of a patient with HCV and B-NHL who achieved SVR with new-generation DAA therapy, and achieved concomitant remission of lymphoma.

DISCUSSION 
In this study we describe for the first time that SOF-based therapy resulted in cure of HCV in a patient who had previously failed many attempts to clear the HCV and also had B-NHL. 
The pathogenesis of the association of HCV infection with B-NHL remains poorly defined and is likely to involve both host (e.g. cirrhosis) [9] and (as yet unknown) viral factors. Based on the evidence for a causal relationship between HCV infection and B-NHL, eradication of HCV infection through effective antiviral regimens could signal prevention of disease progression and remission of concurrent B-NHL [3,4].
Therapeutic options at the time of this patient’s first referral were limited; standard IFN-based regimens were only effective in ~one-half of patients [10] and rates of SVR were particularly low in patients who had failed previous therapies, as observed in our patient. First-generation PIs, boceprevir and telaprevir, were not considered viable options due to risks of drug–drug interactions (DDI) and side effects [11,12]. By 2014, the newer DAAs, ASV and DCV, were considered an attractive option due to high response rates and favourable tolerability seen in treatment-experienced GT 1b patients [8]. However, ASV and DCV have potential for resistance and although initially demonstrated a decrease in viral load, the patient experienced virological breakthrough within 4 weeks of treatment and developed resistance to both agents. These agents were replaced with the HCV NS5B polymerase inhibitor, SOF, which has a high barrier to resistance and limited risk of DDI, making it compatible with many anti-cancer regimens [13,14]. SOF-based regimens have potent pangenotypic antiviral activity, irrespective of treatment history, prior response to treatment and presence of drug-resistant HCV mutants, resulting in cure in many difficult-to-treat patients with chronic HCV [14]. A 12-week regimen of SOF-based therapy resulted in viral clearance and an SVR 12-weeks post-treatment, an indicator of HCV cure [6]. The patient was initially misclassified as HCV GT 1 rather than GT 4. The initial genotyping was conducted before 2011 and was based on an old assay; this suggests re-genotyping is required in clinical practice before new DAA therapy is assigned.
The outcome for our patient was consistent with the findings from clinical studies since, despite failing to achieve negative viraemia during 8 weeks of DCV and/or ASV treatment, he cleared the virus within 8 days on a SOF-based regimen. There was no evidence of lymphoma relapse 3 months after the discontinuation of HCV therapy which may provide further support for a causal link between HCV and B-NHL.
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